icrf 193 has been researched along with Cardiotoxicity in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bavlovič Piskáčková, H; Chládek, J; Jansová, H; Jirkovská, A; Karabanovich, G; Kollárová-Brázdová, P; Kubeš, J; Lenčová-Popelová, O; Melnikova, I; Roh, J; Šimůnek, T; Štěrba, M; Štěrbová-Kovaříková, P; Váňová, N | 1 |
| Austin, CA; Bavlovič Piskáčková, H; Jirkovská, A; Jirkovský, E; Karabanovich, G; Korábečný, J; Kubeš, J; Kučera, T; Melnikova, I; Nováková, L; Roh, J; Šimůnek, T; Skalická, V; Škoda, J; Štěrba, M | 1 |
| Adamcová, M; Holečková, M; Jirkovská, A; Karabanovich, G; Kocúrová-Lengvarská, J; Kollárová-Brázdová, P; Kubeš, J; Lenčová-Popelová, O; Mazurová, Y; Roh, J; Šimůnek, T; Štěrba, M; Štěrbová-Kovaříková, P; Váňová, N | 1 |
3 other study(ies) available for icrf 193 and Cardiotoxicity
| Article | Year |
|---|---|
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
Topics: Animals; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Diketopiperazines; DNA Topoisomerases, Type II; Male; Myocytes, Cardiac; Piperazine; Prodrugs; Rabbits; Razoxane; Topoisomerase II Inhibitors; Water | 2021 |
Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions.
Topics: Animals; Animals, Newborn; Cardiotonic Agents; Cardiotoxicity; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Diketopiperazines; DNA Topoisomerases, Type II; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Myocytes, Cardiac; Piperazines; Protein Binding; Rats, Wistar; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2021 |
Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo.
Topics: Animals; Cardiomyopathies; Cardiotoxicity; Chronic Disease; Daunorubicin; Diketopiperazines; Disease Models, Animal; DNA Damage; Fibrosis; HL-60 Cells; Humans; Male; Myocytes, Cardiac; Prodrugs; Rabbits; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2021 |